Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FLT3 exon 14 ins FLT3 D835del |
| Therapy | Gilteritinib |
| Indication/Tumor Type | hematologic cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FLT3 exon 14 ins FLT3 D835del | hematologic cancer | sensitive | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) treatment inhibited growth of transformed hematologic cells expressing FLT3-ITD and FLT3 D835del in culture (PMID: 35395091). | 35395091 |
| FLT3 exon 14 ins FLT3 D835del | hematologic cancer | sensitive | Gilteritinib | Preclinical - Cell culture | Actionable | In a preclinical study, Xospata (gilteritinib) resulted in reduced cell viability in transformed cells expressing FLT3 ITD with FLT3 D835del in culture (PMID: 32040554). | 32040554 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (32040554) | Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations. | Full reference... |
| (35395091) | The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms. | Full reference... |